Bordetella PlrSR regulatory system controls BvgAS activity and virulence in the lower respiratory tract by Bone, M. Ashley et al.
Bordetella PlrSR regulatory system controls BvgAS
activity and virulence in the lower respiratory tract
M. Ashley Bonea,1, Aaron J. Wilkb,1,2, Andrew I. Peraulta, Sara A. Marlatta,3, Erich V. Schellera, Rebecca Anthouarda,
Qing Chenc, Scott Stibitzc, Peggy A. Cottera,4, and Steven M. Juliob,4
aDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599; bDepartment of Biology, Westmont
College, Santa Barbara, CA 93108; and cDivision of Bacterial, Parasitic, and Allergenic Products, Center for Biologics Evaluation and Research, Food and
Drug Administration, Bethesda, MD 20892
Edited by Scott J. Hultgren, Washington University School of Medicine, St. Louis, MO, and approved January 6, 2017 (received for review June 13, 2016)
Bacterial pathogens coordinate virulence using two-component
regulatory systems (TCS). The Bordetella virulence gene (BvgAS)
phosphorelay-type TCS controls expression of all known protein
virulence factor-encoding genes and is considered the “master vir-
ulence regulator” in Bordetella pertussis, the causal agent of pertus-
sis, and related organisms, including the broad host range pathogen
Bordetella bronchiseptica. We recently discovered an additional sen-
sor kinase, PlrS [for persistence in the lower respiratory tract (LRT)
sensor], which is required for B. bronchiseptica persistence in the
LRT. Here, we show that PlrS is required for BvgAS to become and
remain fully active in mouse lungs but not the nasal cavity, demon-
strating that PlrS coordinates virulence specifically in the LRT. PlrS is
required for LRT persistence even when BvgAS is rendered consti-
tutively active, suggesting the presence of BvgAS-independent,
PlrS-dependent virulence factors that are critical for bacterial sur-
vival in the LRT. We show that PlrS is also required for persistence
of the human pathogen B. pertussis in the murine LRT and we pro-
vide evidence that PlrS most likely functions via the putative cog-
nate response regulator PlrR. These data support a model in which
PlrS senses conditions present in the LRT and activates PlrR, which
controls expression of genes required for the maintenance of BvgAS
activity and for essential BvgAS-independent functions. In addition
to providing a major advance in our understanding of virulence
regulation in Bordetella, which has served as a paradigm for several
decades, these results indicate the existence of previously unknown
virulence factors that may serve as new vaccine components and
therapeutic or diagnostic targets.
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Caused by the human-specific, Gram-negative bacterium Bor-detella pertussis, whooping cough (aka pertussis) is reemerging
in the United States and other developed countries, despite high
vaccine coverage (1, 2). Increased incidence in recent years co-
incides with the switch to acellular vaccines, which induce im-
munity that is less durable than that induced by whole-cell
vaccines or by infection with B. pertussis (3–5). Although closely
related to B. pertussis, Bordetella bronchiseptica infects nearly
all mammals and typically causes more chronic, long-term re-
spiratory infections (6). Despite these differences, B. pertussis and
B. bronchiseptica produce a nearly identical set of virulence factors
that includes adhesins, such as filamentous hemagglutinin (FHA)
and fimbriae (FIM), and toxins, such as adenylate cyclase toxin
(ACT), and a type III secretion system (T3SS) (2).
The Bordetella virulence gene (BvgAS) phosphorelay-type two-
component regulatory system (TCS) is considered the “master
virulence control system” in Bordetella. BvgAS differentially reg-
ulates (either directly or indirectly) hundreds of genes and at least
three distinct phenotypic phases (7, 8). The Bvg+ phase occurs
when the bacteria are grown at 37 °C in Stainer–Scholte (SS) broth
or on Bordet–Gengou (BG) blood agar and correlates with BvgAS
activity. The Bvg+ phase is characterized by expression of all
currently known protein virulence factor-encoding genes (referred
to collectively as vags) and lack of expression of BvgAS-repressed
genes (called vrgs), which includes those encoding flagella in
B. bronchiseptica. The Bvg– phase occurs when the bacteria are
grown at ≤26 °C or when millimolar concentrations of MgSO4 or
nicotinic acid are added to the growth medium (referred to as
“modulating conditions”). The Bvg– phase is characterized by
expression of vrg loci and lack of expression of vags. The Bvg-
intermediate (Bvgi) phase occurs at intermediate temperatures
or in the presence of low concentrations of MgSO4 or nicotinic
acid (9). It is characterized by expression of vags that contain
high-affinity BvgA binding sites at their promoters (such as fhaB,
encoding FHA, fimBCD, encoding the FIM biogenesis proteins,
and bvgAS itself), lack of expression of vags with low-affinity
BvgA binding sites (such as cyaABDE, encoding ACT and ptxA-E,
encoding pertussis toxin), lack of expression of vrgs, and maximal
expression of bipA, which encodes an outer-membrane protein of
unknown function (9–11). Although BvgAS activity is altered by
temperature, MgSO4, and nicotinic acid in vitro, the true signals it
senses in nature are unknown.
B. pertussis and B. bronchiseptica strains containing loss-of-
function mutations in bvgAS are avirulent, whereas strains con-
taining mutations that render BvgAS active—even under modu-
lating conditions in vitro—are indistinguishable fromWT bacteria
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in their ability to cause respiratory tract infections (12–14).
Characterization of antibody responses following infection and
analyses using recombination-based reporters of gene expression
indicate that modulation to the Bvg– phase does not occur during
infection (12, 15, 16). Studies with strains that produce Bvg–
phase factors ectopically in the Bvg+ phase have demonstrated
the importance of BvgAS-mediated repression of gene expres-
sion in vivo (14, 17). Taken together, these results have been
interpreted to indicate that the Bvg+ phase is both necessary and
sufficient for the development of respiratory infection by Bordetella.
Moreover, these data, together with the fact that the phenotypic
profile of WT bacteria grown at 37 °C in SS medium or on BG agar
(Bvg+ phase conditions) is identical to that of mutants containing
bvgS mutations that render BvgS insensitive to modulating condi-
tions, have led to the conclusion that these in vitro growth condi-
tions mimic, at least to some extent, those experienced by the
bacteria in the respiratory tract.
In a survey of putative TCSs in B. bronchiseptica, we discov-
ered a gene (BB0264) predicted to encode an NtrY-like sensor
kinase that is essential for B. bronchiseptica to colonize the tra-
chea of rats following low-dose, low-volume intranasal in-
oculation and to persist in the lungs of mice following high-dose,
large-volume intranasal inoculation (18). We named BB0264
plrS, for persistence in the lower respiratory tract (LRT) sensor.
Subsequently, Hester et al. reported the identification of a CO2
responsive regulon in Bordetella, and hypothesized that CO2
gradients may be sensed by the bacteria as a cue indicating their
localization in the LRT (19). Here, we show that plrS is required
for increased virulence factor production in response to CO2,
suggesting a functional link between PlrS and BvgAS. We in-
vestigated this link, showed that plrS is required for BvgAS to be
fully active in the LRT, and showed that plrS is required for
persistence in the LRT even when BvgAS is constitutively active,
indicating that although BvgAS is necessary in vivo, it is not
sufficient. Moreover, our data suggest the existence of genes that
are expressed only in the LRT that encode previously unknown
virulence factors, which may serve as new therapeutic or di-
agnostic targets and vaccine components.
Results
PlrS Is Required for Enhanced BvgAS-Dependent Virulence-Associated
Phenotypes in Response to Elevated CO2 Concentrations. BvgAS-
regulated virulence-associated phenotypes include adherence to
epithelial cells and macrophages, which is mediated by FHA (20,
21), hemolysis on blood-containing agar, which is mediated by
ACT (22), and toxicity to various eukaryotic cell types in culture,
which is mediated, at least in part, by the T3SS (23). All of these
phenotypes were enhanced when WT B. bronchiseptica was
grown at 37 °C in 5% CO2 compared with growth at 37 °C in
ambient air (Fig. 1 and Fig. S1) (19). These virulence-associated
phenotypes did not increase in response to 5% CO2 in the ΔplrS
mutant, indicating that PlrS is required for this effect. The effect
was not a result of acidification of the growth medium because
acidification alone, without increased CO2, did not result in in-
creased adherence (Fig. S2). These results suggest the possibility
of a functional interaction between PlrS and BvgAS.
PlrS Likely Affects BvgAS-Dependent Phenotypes via PlrR.A putative
response regulator, which we are naming PlrR, is encoded im-
mediately 3′ to plrS. Multiple attempts using various approaches
to disrupt or delete plrR (BB0265) were unsuccessful, suggesting
plrR is essential for cell viability under the growth conditions
tested. As an alternate approach to determine if PlrS and PlrR
function as a cognate TCS, we delivered a plrR allele (plrRD52E)
encoding a PlrR protein in which the predicted site of phosphor-
ylation, Asp52, was replaced with Glu, a predicted phosphomimetic
(24), to the attTn7 site in WT, ΔplrS, and ΔbvgS (which harbors a
deletion in bvgS) B. bronchiseptica. When grown in 5% CO2, the
level of adherence of the ΔplrS strain expressing plrRD52E to L2
cells was as high as that of WT B. bronchiseptica (and WT-
expressing plrRD52E), demonstrating that the plrRD52E allele could
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Fig. 1. PlrS is required for Bvg-dependent phenotypes in 5% CO2 growth
conditions. (A) Bacterial adherence to L2 lung epithelial cells. WT and ΔplrS
bacteria were cultured in ambient (37 °C) or 5% CO2 (37 °C + 5% CO2)
conditions before inoculation at an MOI of 150 onto an L2 monolayer. The
number of adherent bacteria per L2 cell was enumerated by determining
the average number of bacteria and L2 cells visible from four visual fields of
the microscope. Error bars represent SD of the mean. (B) Hemolysis on blood
agar media produced fromWT, ΔplrS, and RB515 (an ACT-null mutant) colonies
under the indicated growth condition. (Magnification, 1,000×.) (C) Cytotoxicity
of macrophage-like J774 cells induced by WT, ΔplrS, ΔbscN (containing an in-
sertional disruption in the gene encoding the ATPase of the T3SS), and ΔbvgS
(containing a deletion in bvgS) strains, following bacterial growth under the
indicated condition. Percent cytotoxicity was calculated as the ratio of lysed
J774 cells resulting from bacterial inoculation to fully lysed J774 cells, and error
bars represent SD. Statistical significance for A (t test with Welch’s correction)
and C (ANOVA) is indicated as *P < 0.05, **P < 0.01, and ****P < 0.0001.
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complement a ΔplrS mutation and, therefore, that PlrS likely
affects BvgAS-dependent virulence-associated phenotypes via
PlrR (Fig. 2). Increased adherence in the WT and ΔplrS strains
expressing plrRD52E in bacteria grown in ambient air is also
consistent with the D52E substitution functioning as a phos-
phomimetic, rendering PlrR constitutively active (Fig. 2). Lack
of adherence by the ΔbvgS strain with and without the plrRD52E
allele in the presence or absence of 5% CO2 confirms that bvgS is
required for adherence to host cells and that PlrRD52E does not
induce a BvgAS-independent adherence activity (Fig. 2). These
data provide evidence (but do not prove) that PlrS and PlrR
function as a canonical TCS, and that increased adherence in
response to CO2 is mediated by PlrS via PlrR. However, these
data do not rule out the possibility that BvgA and PlrR interact
synergistically to affect expression of some genes or that PlrS
directly interacts with BvgS, while also affecting the phosphory-
lation state of PlrR.
Positive autoregulation of the bvgAS operon is well-docu-
mented (25–28). Nonetheless, to determine if PlrS affects BvgAS
activity by controlling bvgAS transcription, we introduced a PbvgA-gfp
transcriptional reporter into the attTn7 site of WT and ΔplrS
B. bronchiseptica, and measured GFP activity in bacteria grown at
37 °C with and without 5% CO2. Under all conditions tested the
levels of GFP—and therefore the expression of bvgAS—was not
significantly different between WT and the ΔplrS strains (Fig. S3).
GFP levels in the ΔbvgS strain reflect activity from the bvgA P2
promoter, which is expressed at a low level under Bvg– phase
conditions (providing the cell with a low amount of BvgAS so that it
can respond, via positive autoregulation, when Bvg+ phase condi-
tions are encountered) (29). This low-level expression of PbvgA was
not affected by the ΔplrS mutation. Taken together, these data
suggest that PlrS, via PlrR, exerts its effects on BvgAS activity
posttranscriptionally.
B. bronchiseptica Lacking plrS Modulate to the Bvg– Phase Within the
LRT. Based on the functional link between PlrS and BvgAS (Fig. 1)
and the similarly rapid clearance of B. bronchiseptica ΔplrS and
ΔbvgS mutants from the LRT of mice (13, 18), we hypothesized
that PlrS may influence BvgAS activity within the host. To test
this hypothesis, we used two reporter systems developed in our
laboratory. pGFLIP contains a recombinase-based reporter sys-
tem, similar to recombinase-based in vivo technology (15). Ex-
pression of flp, encoding FLP recombinase, results in excision of
gfp and nptII (encoding kanamycin resistance, Kmr) genes lo-
cated between FLP recombinase target (FRT) sites and con-
version of the bacteria from GFP+ and Kmr to GFP– and Kms. In
pGFLIP-flaA, the Bvg– phase-specific PflaA promoter is located
5′ to flp and conversion to GFP– (and Kms) indicates that the
bacteria have expressed the Bvg– phase at some point during
the experiment.
In contrast to pGFLIP, which reports on the history of the
bacteria, the pBAM plasmid reports on the status of the bacteria
at the time of plating (29). The pBAM plasmid integrates within
the bvgAS promoter region and causes the P2 promoter to be
expressed at a lower-than-normal level such that, when bacteria
are growing under Bvg– phase conditions, the amount of BvgAS
in a small proportion of cells in the population (∼5%) is below
the threshold required for positive autoregulation, “trapping”
these cells in the Bvg– phase (29). When WT B. bronchiseptica
containing the pBAM plasmid are grown under Bvg– phase
conditions and then plated onto BG-blood agar and incubated at
37 °C (Bvg+ phase conditions), the trapped bacteria yield colo-
nies that are larger, flatter, and less hemolytic than colonies
formed by Bvg+ phase bacteria because these colonies contain
∼5% phenotypically Bvg– phase bacteria (as the colony grows,
∼95% of the daughter cells produce enough BvgAS to convert to
the Bvg+ phase, whereas ∼5% remain phenotypically Bvg–
phase). We previously referred to these colonies, which are easily
scored by simple visual inspection, as large colony variants (29).
However, because these colonies result from phenotypic bist-
ability and not a genetic change, it is more appropriate to refer to
them as large colony phenotypes (LCPs), which we will do
henceforth. Although all LCPs result from a founder bacterium
that was Bvg– phase at the time of plating, ∼95% of bacteria that
Fig. 2. Overexpression of a phosphomimetic plrR allele rescues the ΔplrS L2 cell adherence defect. L2 lung epithelial cell adherence displayed by WT, ΔplrS,
WT-plrRD52E (a strain isogenic to WT that produces PlrR with the phosphomimetic D52E substitution), ΔplrS-plrRD52E (ΔplrS that produces PlrR with
the phosphomimetic D52E substitution), ΔbvgS, and ΔbvgS-plrRD52E (ΔbvgS that produces PlrR with the phosphomimetic D52E substitution) following
bacterial growth under the indicated condition. Error bars represent SD of the mean. Statistical significance (t test with Welch’s correction) is indicated as
****P < 0.0001.
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contain pBAM and are Bvg– phase at the time of plating form
typical Bvg+ phase-appearing (non-LCP) colonies (29). Hence,
although the presence of LCPs indicates that bacteria have mod-
ulated to the Bvg– phase, it vastly underestimates the number of
bacteria that are Bvg– phase at the time of plating.
When grown at 37 °C without addition of MgSO4 to the me-
dium (Bvg+ phase conditions), WT and ΔplrS strains containing
both reporter systems maintained GFP fluorescence and no
LCPs formed (Fig. S4), indicating that neither strain modulated
to the Bvg– phase. When switched from Bvg+ phase growth
conditions to Bvg– phase growth conditions, both strains lost
GFP fluorescence and a small proportion of LCPs formed after
24 h (Fig. S4). Both reporters, therefore, can accurately report
that the bacteria modulated to the Bvg– phase and ΔplrSmutants
modulate to a similar extent as WT bacteria when grown in vitro.
Following intranasal inoculation of BALB/cJ mice, the num-
bers of cfu recovered from the nasal cavities and lungs of WT
and ΔplrS strains containing the reporters were similar to cfu
recovered of the parental strains (without reporters), indicating
that the reporters do not influence virulence (Fig. 3A). The pro-
portion of GFP– and LCP cfu recovered from the nasal cavities
was extremely low for both strains, indicating that the bacteria did
not modulate to the Bvg– phase at this site (Fig. 3 B and C). The
proportion of GFP– and LCP cfu recovered from the lungs of
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Fig. 3. Without PlrS, B. bronchiseptica modulates to the Bvg– phase in the LRT. (A) Colonization of the nasal cavity (Upper) and right lung (Lower) for WT
(filled circles) and ΔplrS (red triangles) on days 0, 1, and 3 postinoculation. Both strains contain the plasmid reporters pGFLIP-PflaA and pBam. Female BALB/cJ
mice were inoculated with 7.5 × 104 cfu via the external nares. Each symbol represents a single animal, with the mean colonization depicted as short hor-
izontal bars. Homogenate from each organ was assessed to determine in vivo bacterial modulation shown in graphs in B and C. (B) Percentage of GFP–
bacteria recovered from the nasal cavity and right lung for WT and ΔplrS containing pGFLIP-PflaA and pBam. GFP negativity indicates bacterial modulation.
(C) Percentage of LCP-producing bacteria recovered from the nasal cavity and right lung for WT and ΔplrS containing pGFLIP-PflaA and pBam. LCPs indicate
bacteria present in the Bvg– phase when plated. (D) Colonization of the nasal cavity (Upper) and right lung (Lower) for WT (filled circles) and ΔplrS (red
triangles) containing the plasmid reporter, pGFLIP-PptxA. Homogenate from each organ was assessed to determine BvgAS activation in vivo, shown in graph in
E. (E) Percentage of GFP– bacteria recovered from the nasal cavity (Upper) and right lung (Lower) for WT and ΔplrS containing pGFLIP-PptxA. GFP negativity
indicates BvgAS activation. Statistical significance (Mann–Whitney) is indicated as *P < 0.05 and **P < 0.01.
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mice inoculated with WT bacteria was also extremely low. In
contrast, 40–80% of the cfu recovered from the lungs of mice in-
oculated with the ΔplrS strain had lost GFP fluorescence and 10–
80% formed LCPs by day 1 postinoculation (Fig. 3 B and C),
indicating that a majority of these bacteria had modulated to the
Bvg– phase and that a majority of these bacteria were in the Bvg–
phase at the time of recovery from the lungs. These findings
demonstrate that in strains lacking plrS, the BvgAS phosphorelay
fails to remain active specifically within the LRT. Moreover, the
fact that 10–80% of the bacteria recovered from the lungs formed
LCPs (i.e., much more than 5%) indicates that the physiology of
ΔplrS bacteria in the LRT is substantially different from the
physiology of ΔplrS bacteria that have modulated to the Bvg– phase
in vitro by chemical modulators such as MgSO4 (Discussion).
B. bronchiseptica Lacking plrS Fail to Activate BvgAS Within the LRT.
To determine if BvgAS can transition from an inactive (Bvg–
phase) to an active (Bvg+ phase) state in the absence of PlrS ac-
tivity within the LRT, we inoculated mice with WT and ΔplrS
mutants containing a pGFLIP reporter in which the Bvg+ phase-
specific ptxA promoter from B. pertussis was cloned 5′ to flp. Both
WT and ΔplrS strains activated the ptxA promoter when switched
from Bvg– phase to Bvg+ phase growth conditions in vitro (Fig. S5).
Similar to what has been shown in B. bronchiseptica and B. pertussis
previously (15, 16), 100% of the bacteria recovered from both the
nasal cavity and the lungs of mice inoculated with Bvg– phase WT
bacteria activated PptxA, and therefore transitioned to a Bvg
+ phase
within 24 h postinoculation (Fig. 3 D and E). In contrast, although
all of the cfu recovered from the nasal cavities of mice inoculated
with the ΔplrS strain were GFP– by 24 h postinoculation, only
∼80% of those recovered from the lungs were GFP– (Fig. 3 D and
E). Although, based on this reporter, only a seemingly small pro-
portion of the ΔplrS mutants failed to switch to the Bvg+ phase in
vivo, it is important to note that the numbers of cfu of the ΔplrS
mutant recovered from the lungs at days 1 and 3 postinoculation
were ∼0.5 and 2 logs lower than the numbers initially present (day
0). It is impossible to determine if the bacteria cleared from the
lungs at these time points had lost GFP. However, if they remained
GFP+ (indicating that they did not switch to the Bvg+ phase), then
the proportion of ΔplrS bacteria that had transitioned to the Bvg+
phase in the LRT would in fact be far less than 1%. Taken to-
gether, our data indicate that full activation and maintenance of
BvgAS activity in the LRT requires PlrS.
PlrS Is Required for B. bronchiseptica Persistence in the LRT,
Independent of Its Effects on BvgAS Activity. Lack of production
of BvgAS-dependent virulence factors could be the reason that
plrS mutants are cleared rapidly from the LRT. To test this hy-
pothesis, we introduced the bvgS-C3 mutation, which encodes a
BvgS protein that is active even under modulating conditions in
vitro (12), into the plrS mutant, and compared this ΔplrS-bvgSc
strain with the bvgSc mutant in vitro and in vivo. Like the bvgSc
strain, the ΔplrS-bvgSc strain formed small, domed, hemolytic
colonies characteristic of the Bvg+ phase on BG-blood agar
containing 50 mM MgSO4 (i.e., Bvg
– phase conditions), in-
dicating that BvgAS was constitutively active in the absence of
plrS in vitro. In vivo, the ΔplrS-bvgSc strain colonized and per-
sisted in the nasal cavity similarly to the bvgSc and ΔplrS strains
(Fig. S6). However, the ΔplrS-bvgSc strain was cleared from the
lungs as rapidly as the ΔplrS mutant (Fig. S6), indicating that the
ΔplrS mutation is epistatic to the bvgS-C3 mutation with regard
to persistence in the LRT.
A CB
Fig. 4. PlrS is required for persistence of B. bronchiseptica in the LRT independent of BvgAS activity. (A) Colonization of the nasal cavity (Upper) and right
lung (Lower) B. bronchiseptica containing constitutively active BvgS (bvgSc; black squares), ΔplrS (red triangles), and ΔplrS-bvgSc (blue squares) on days 0, 1,
and 3 postinoculation. All strains contain the plasmid reporters pGFLIP-PflaA and pBam. Female BALB/c mice were inoculated with 7.5 × 10
4 cfu via the external
nares. Each symbol represents a single animal, with the mean colonization depicted as short horizontal bars. Homogenate from each organ was assessed to
determine in vivo bacterial modulation shown in graphs in B and C. (B) Percentage of GFP– bacteria recovered from the nasal cavity and right lung for bvgSc,
ΔplrS, and ΔplrS-bvgSc containing pGFLIP-flaA and pBam. GFP negativity indicates bacterial modulation. (C) Percentage of LCP producing bacteria recovered
from the nasal cavity and right lung for bvgSc, ΔplrS, and ΔplrS-bvgSc containing pGFLIP-PflaA and pBam. LCPs indicate bacteria present in the Bvg– phase
when plated. Statistical significance (Mann–Whitney) is indicated as *P < 0.05 and **P < 0.01.
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To investigate BvgAS activity in the ΔplrS-bvgSc strain, we used
our pGFLIP-flaA and pBAM reporters. None of the bvgSc or
ΔplrS-bvgSc colonies containing these reporters were GFP– or
displayed the LCP phenotype after growth in medium containing
50 mM MgSO4 (Fig. S7), indicating their insensitivity to modu-
lating conditions in vitro. Numbers of cfu of each strain recovered
from the nasal cavities and lungs of BALB/cJ mice were similar to
those of the strains lacking the pGFLIP-flaA and pBAM reporters
(Fig. 4A). Additionally, very few, if any, GFP– or LCP colonies
were recovered from the nasal cavity for any strain, indicating that
no bacteria had modulated to the Bvg– phase in the nasal cavity
(Fig. 4 B and C). As expected, a significant proportion of GFP–
colonies and LCPs were recovered from the lungs of mice in-
oculated with the ΔplrS mutant on days 1 and 3, consistent with
our previous results (Fig. 4 B and C). In contrast, no GFP– or LCP
colonies were recovered from the lungs of mice inoculated with
the bvgSc or ΔplrS-bvgSc mutants (Fig. 4 B and C), indicating that
neither strain modulated to the Bvg– phase in the LRT. Therefore,
modulation to the Bvg– phase and lack of BvgAS-activated viru-
lence factors is not the only reason that ΔplrS mutants fail to
persist in the LRT. These data indicate that PlrS is required for
bacterial persistence in the LRT, even when BvgAS remains ac-
tive, likely because PlrR (presumably phosphorylated PlrR,
PlrR∼P) activates expression of one or more genes encoding
proteins that are required in this environment or because PlrR∼P
represses expression of one or more genes that encode proteins
that are detrimental to survival in this environment.
PlrS Is Required for Survival and Persistence of B. pertussis in the LRT.
The plrSR locus is highly conserved (≥99% identical) among all
strains of the classic bordetellae (B. pertussis, B. bronchiseptica,
and Bordatella parapertussis). We constructed a derivative of
B. pertussis strain BP536 with a large in-frame deletion mutation in
plrS and compared it with WT BP536 in BALB/cJ mice. Both
strains colonized the nasal cavity at similar levels, and were
cleared from this site by day 3 postinoculation (Fig. 5). However,
whereas ∼103 cfu of BP536 were recovered from the lungs on days
1 and 3 postinoculation, significantly fewer BP536ΔplrS cfu were
recovered from this site at these time points (Fig. 5). These data
indicate that similar to B. bronchiseptica, plrS is required for the
survival and persistence of B. pertussis specifically in the LRT.
Discussion
BvgAS has been considered the master virulence regulator in
Bordetella since its identification in 1983 (30) and demonstration
of its penetrance by subsequent mutagenesis and genome-wide
analyses (8, 31, 32). Our new data indicate, however, that in the
LRT, BvgAS activity depends on PlrS, likely via the activity of
PlrR. Moreover, PlrS(R) is required for bacterial survival in the
LRT even when BvgS is rendered constitutively active, strongly
suggesting that one or more PlrSR-dependent, BvgAS-independent
genes (or genes that require both PlrSR and BvgAS) is required for
bacterial survival at this site. PlrS(R) is therefore at least as im-
portant for Bordetella virulence as BvgAS.
Why is PlrS(R) required for bacterial persistence in the LRT?
PlrSR belongs to the NtrYX family of TCS. NtrY family proteins,
including PlrS, are predicted to contain three transmembrane do-
mains at their N termini, followed by a periplasmically located PhoP-
DcuS-CitA (PDC) domain, another transmembrane domain, then
cytoplasmically located HAMP, Per-Arnt-Sim (PAS), and HisKA-
type histidine kinase domains (Fig. 6.). NtrY of Brucella abortus has
been shown to bind heme via its PAS domain and to function as a
redox sensor, becoming active as a kinase in response to anaerobiosis
(33). NtrX family response regulators contain N-terminal receiver
and C-terminal DNA binding domains. In Neisseria gonorrheae and
Rhodobacter capsulatus, the ntrX genes are required for induction of
high-affinity cytochrome oxidases, which are required for bacterial
growth under low oxygen conditions (34). Our data indicate that PlrS
is required specifically in the LRT, an environment that is low in
oxygen and high in CO2. Although we have been unable to delete
plrR in vitro, our experiments using PlrRD52E indicate that PlrS
affects BvgAS-dependent phenotypes in vitro via PlrR (providing
evidence, but not proving, that PlrS and PlrR function as a TCS).
It seems likely that PlrS functions through PlrR in vivo as well. By
analogy with the few other NtrYX family members that have been
studied so far, we hypothesize that PlrS senses low oxygen (and
perhaps increased CO2) in the LRT, phosphorylates PlrR, and
that PlrR∼P activates expression of one or more of the high-
affinity cytochrome oxidase-encoding loci present in B. bronchiseptica
(and B. pertussis) (35), allowing the bacteria to respire in this envi-
ronment (Fig. 6). We note, however, that NtrY family members,
including PlrS, contain HisKA-type DHp domains with ExxN motifs
that suggest that these proteins possess both kinase and phosphatase
activities (36–38). Although our data suggest that PlrS may function
to phosphorylate PlrR in vitro, especially in 5% CO2, the contribu-
tions of its predicted kinase and phosphatase activities in vivo cannot
be predicted from our current data.
Why is PlrS(R) required for BvgAS activity in the LRT?
Positive autoregulation by BvgAS has been well-characterized
(25–28, 39) and we showed here that bvgAS expression in both
ambient air and 5% CO2 is not dependent on plrS, by evaluating
activity of the bvgAS promoter from a single-copy chromosomal
reporter (to avoid issues that arise when multicopy plasmids are
used) while also leaving the native bvg locus intact, thereby
preserving the positive autoregulation capability of BvgAS dur-
ing the experiment. Our data demonstrate that although bvgAS
autoregulation (the only known mechanism that affects bvgAS
expression) remains intact, plrS does not influence bvgAS expres-
sion. Moreover, our experiments with the bvgSc mutant further
Fig. 5. PlrS is required for the persistence of B. pertussis in the LRT. Colo-
nization of the nasal cavity (Upper) and right lung (Lower) for B. pertussis
strains BP536 (filled circles) and BP536ΔplrS (red diamonds) on days 0, 1, and
3 postinoculation. Female BALB/c mice were inoculated with 1.0 × 105 cfu via
the external nares. Each symbol represents a single animal, with the mean
colonization depicted as short horizontal bars. Statistical significance
(Mann–Whitney) is indicated as **P < 0.01.
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indicate that bvgAS expression is not dependent on PlrS(R) in
vivo because BvgAS in the ΔplrS-bvgSc strain—which contains a
single nucleotide substitution in bvgS, rendering the BvgS protein
constitutively active—was active in the LRT. If bvgAS tran-
scription required PlrSR, the ΔplrS mutation would be epistatic
to the bvgS-C3 mutation with regard to BvgAS activity. Our data
therefore rule out the possibility that PlrS(R) controls BvgAS
activity by controlling bvgAS transcription. We hypothesize that
instead, PlrSR controls expression of one or more genes that encode
proteins required for BvgS activity specifically in the LRT. BvgS
contains three predicted signal-sensing domains: two periplasmically
located Venus flytrap domains (VFT) and a cytoplasmically located
PAS domain (40, 41). Although the VFT appear to convert BvgS
into a phosphatase that dephosphorylates BvgA in response to
modulating conditions (i.e., MgSO4 or nicotinic acid) (42–44), a role
for the PAS domain has not been established. However, bio-
chemical analyses using the cytoplasmic portion of BvgS suggested
that the redox state of ubiquinone could affect BvgS kinase ac-
tivity (45). PlrSR-dependent production of high-affinity cyto-
chrome oxidases would allow electron transport-coupled oxidative
phosphorylation to occur in the LRT, which is required for ATP
production (and hence cell viability), and for preventing the ac-
cumulation of reduced ubiquinone, which could inactivate BvgS.
This model is consistent with that proposed for the ArcB protein
of Escherichia coli, which is activated by low-oxygen conditions
(46, 47). If true, this model would predict that a role for the PAS
domain in sensing signals in vitro may have been missed because
the activity of low-affinity (high-efficiency) cytochrome oxidases
present under all of the conditions tested would keep reduced
ubiquinone levels at a minimum. These low-affinity cytochrome
oxidases are also likely present and sufficient for respiration in
the upper respiratory tract, making BvgS activity and bacterial
survival at this site independent of PlrS.
Why was the proportion of LCPs recovered from the lungs of
mice inoculated with the ΔplrS strain so much higher than the
proportion obtained after switching the bacteria from Bvg– phase
conditions to Bvg+ phase conditions in vitro? Our previous
studies showed that the reason that ∼5% of bacteria containing
the pBAM plasmid integrated at the bvgAS promoter region
form LCPs when shifted from Bvg– phase conditions to Bvg+
phase conditions in vitro, is that activity of the P2 promoter in
this strain is decreased such that ∼5% of the bacteria have
BvgAS levels below the threshold required to respond to Bvg+
phase conditions when they are encountered. It appeared, there-
fore, that the maximum proportion of LCPs that would form from
a population of pBAM-containing bacteria in which 100% of the
bacteria had modulated to the Bvg– phase was about 5%.We were
surprised, therefore, to find that the proportion of LCPs formed
after recovery of the ΔplrS mutant from the lungs of mice was up
to 80%. Given that the activity of the P2 promoter is already
Fig. 6. PlrSR and BvgAS work in tandem to regulate gene expression required for Bordetella persistence in the LRT. Model of putative PlrSR and BvgAS
regulatory networks in Bordetella. The sensor kinase PlrS may be sensitive to CO2 or oxygen tension, directly or indirectly, within the LRT environment,
transmitting a signal via autophosphorylation and phosphate transfer to its putative response regulator PlrR. PlrSR activates (pags) or represses (prgs), a set of
genes independent of BvgAS that are required for survival of the bacteria specifically within the LRT. PlrSR may also regulate expression of a gene encoding a
protein required for sustained activity of BvgAS in the LRT. If BvgS receives such a signal the sensor kinase is capable of phosphorelay transmission, activating
transcription of essential virulence factors (vags) and repressing transcription of Bvg– phase genes (vrgs).
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extremely low, it seems unlikely that P2 promoter activity in the
ΔplrS mutant is substantially lower in the LRT than under Bvg–
phase conditions in vitro. A more likely possibility is that the
physiology of the ΔplrS mutant in the LRT is substantially dif-
ferent from the physiology of the ΔplrS mutant growing under
Bvg– phase conditions in vitro (and from WT bacteria in the
LRT, which do not modulate to the Bvg– phase), and that this
altered physiology prevents or delays BvgS from reactivating
upon exposure to Bvg+ phase conditions in vitro. If PlrS(R)
controls expression of cytochrome oxidases in the LRT, and if
BvgS is sensitive to the redox state of ubiquinone, then BvgS
would be inactive in a plrS mutant in the LRT and would not
become active again until cytochrome oxidase activity reached
levels sufficient to reoxidize ubiquinone pools, which, in the case
of a plrS mutant, could require expression of genes encoding low-
affinity cytochrome oxidases, translation of proteins, and assem-
bly of enzymatic complexes in the membrane after the bacteria
are shifted to Bvg+ phase conditions in ambient air. This delay
could account for the substantially higher proportions of LCPs
formed by the plrS mutant recovered from the LRT compared
with the proportion formed after growth in vitro.
Challenging the long-held paradigm that the Bvg+ phase is
sufficient for respiratory infection and evidence that virulence
factors that require PlrS(R) independently of (or codependently
with) BvgAS exist is important from a translational medicine per-
spective. B. bronchiseptica and B. pertussis are sufficiently closely
related to be considered members of the same species (35), and
several vags have been shown to be functionally interchangeable
(48–51). As in B. bronchiseptica, a B. pertussis plrS mutant was
defective in persistence in the LRT. Our model for the role of
PlrSR during infection based on studies with B. bronchiseptica is
therefore likely to apply to B. pertussis as well. In addition to
mounting evidence that acellular and whole-cell vaccines provide
suboptimal protection that is less durable than that induced by
infection with B. pertussis, recent data from studies with baboons
indicate that although both vaccines protect against disease,
neither protects against colonization (52). Moreover, baboons
vaccinated with an acellular vaccine and then challenged with
B. pertussis were able to transmit the disease to naïve animals,
even though they exhibited no signs of illness (52). The fact that
infection induces a mixed Th1/Th17-type immune response and
acellular vaccines induce a strong Th2-type immune response
(4, 53–56) suggests that reformulation of acellular vaccines with
adjuvants to induce a Th1/Th17 response is a reasonable ap-
proach to controlling the reemergence of pertussis. However,
the phenomenon of epitope-linked suppression would likely
render such vaccines ineffective in individuals previously vac-
cinated with acellular vaccines and perhaps also in those vac-
cinated with whole-cell vaccines, which are prepared from in
vitro grown bacteria. Inclusion of antigens not present in pre-
vious vaccines would avoid this problem. The existence of vir-
ulence factors that are produced only in the host during
infection, as suggested by our data, is significant from this
translational medicine perspective. Antigens that are produced
only during infection could also be important diagnostically as a
means to distinguish individuals who have been vaccinated
from those who have been infected. Finally, PlrSR itself, and
factors it controls, may be exploitable as therapeutic targets.
Materials and Methods
In Vitro Adherence Assays. Bacterial adherence to rat lung epithelial (L2) cells
was evaluated as described previously (21, 48). Bacteria were cultured in
either ambient air or 5% CO2 at 37° to an OD600 of ∼1.0. Bacteria were
added to a monolayer of L2 cells (∼80% confluency) at a multiplicity of in-
fection (MOI) of 150. Adherence was visualized by Giemsa staining and light
microscopy at 1,000× magnification using a Zeiss Axiostar microscope, and
quantified by counting the number of adherent bacteria and total L2 cells in
at least four microscopic fields.
Macrophage Cytotoxicity Assays. J774 macrophage-like cells were grown to
∼60% confluency (∼1.5 × 104 cells per well) in a 96-well microtiter dish.
Bacteria were cultured in either ambient air or 5% CO2 to an OD600 of ∼1.0,
and were then added to J774 cells at an MOI of 150. The plate was spun at
1,200 × g and then allowed to incubate in a tissue culture incubator for 3 h.
Macrophage cytotoxicity was quantified by measuring lactate dehydroge-
nase release using Promega’s Cytotox96 Nonreactive Cytotoxicity Assay kit
and a MultiskanEX plate reader (ThermoFisher Scientific) according to the
manufacturer’s instructions.
Bacterial Colonization of the Mouse Respiratory Tract. Six-week-old female
BALB/cJ mice from Jackson Laboratories were inoculated intranasally with
7.5 × 104 cfu B. bronchiseptica or 1.0 × 105 cfu B. pertussis in 50 μL of PBS. For
all time points, right lung lobes and nasal cavities were harvested, tissues
were homogenized, and the number of cfu was determined by plating di-
lutions of tissue homogenates on BG blood agar.
Evaluation of B. bronchiseptica Phenotypic Phase Transition in Vivo. Six-week-
old female BALB/cJ mice (Jackson Laboratories) were inoculated intranasally
with 7.5 × 104 cfu of B. bronchiseptica pGFLIP strains in 50 μL of PBS. For
experiments using the pGFLIP-PptxA reporter, bacteria were cultured in
media containing 50 mM MgSO4 to maintain the bacteria in the Bvg
– phase
before mouse inoculation (15). For infections using the pGFLIP-PflaA or
pBam systems, bacteria were cultured at 37 °C in media without the addition
of MgSO4 to maintain bacteria in the Bvg
+ phase before mouse inoculation
(15, 29). On days 0, 1, and 3 postinoculation, right lungs were harvested,
homogenized in PBS, and plated in duplicate on BG-blood agar. For strains
containing the pGFLIP-PptxA system, homogenization, dilution, and plating
were carried out in the presence of 50 mM MgSO4. The percent GFP
– colo-
nies and percent LCP colonies were calculated by determining the ratio of
GFP– or LCP colonies to the total number of colonies isolated. See Table S1
for strains and plasmids used in this study.
Ethics Statement. This study was carried out in strict accordance with the rec-
ommendations in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health (57). Our protocol was approved by the University
of North Carolina Institutional Animal Care and Use Committee (Protocol ID: 13-
238). All animals were properly anesthetized for inoculations, monitored reg-
ularly, and killed when moribund. Efforts were made to minimize suffering.
Statistical Analysis. Statistical analysis was performed using Prism 6.0 software
from GraphPad Software. Statistical significance was determined using un-
paired Student’s t test with Welch’s correction, a Mann–Whitney test, or
ANOVA test. Figures were generated using Adobe Illustrator CS6 (Adobe
Systems). P < 0.05 was considered significant.
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